教授
当前位置: 9001cc金沙 > 师资队伍 > 教授 > 正文
肖波
发布时间: 2024-02-02 09:44  作者:   编辑:院办公室   审核:   来源:9001cc金沙   浏览次数:


个人简介

肖波,博士,教授。先后入选“2020全球前2%顶尖科学家2021年),国家级青年人才计划(2021年),重庆市委组织部青年拔尖人才2018年)等。

主要研究方向:1.新型药物递送系统,利用天然物质作为纳米药物或药物(如siRNA、化学药物等)的载体材料,设计并构建各种新型纳米粒子、微米粒子、水凝胶或纤维等载药系统,用于细菌感染、炎症和肿瘤等疾病的治疗。2. 再生医学:选用具有优良生物相容性的天然高分子及其衍生物(如丝素蛋白、丝胶、透明质酸等)或/和合成高分子(如PLGAPCL等)材料,与细胞、细胞因子、药物等结合,制备纳米纤维薄膜、水凝胶等,以达到疾病原位治疗的目的。

代表论文

1. Ya Ma, Lian Duan, Jianfeng Sun, Shuangquan Gou, Fengyuan Chen, Yuqi Liang, Fangyin Dai, and Bo Xiao*. Oral nanotherapeutics based on Antheraea pernyi silk fibroin for synergistic treatment of ulcerative colitis. Biomaterials2022;282:121410. IF = 12.4

2. Chen Q., Li Q., Liang Y., Zu M., Chen N., Canup B., Luo L., Wang C.*, Zeng L.*, and Xiao B.* Natural exosome-like nanovesicles from edible tea flowers suppress metastatic breast cancer via ROS generation and microbiota modulation. Acta Pharm. Sin. B 2022;12(2):907-923. (IF = 11.4

3.Shuangquan Gou, Nanxi Chen, Xiaoai Wu, Menghang Zu, Shixiong Yi, Binwu Ying*, Fangyin Dai, Bowen Ke*, Bo Xiao*. Multi-responsive nanotheranostics with enhanced tumor penetration and oxygen selfproducing capacities for multimodal synergistic cancer therapy. Acta Pharm. Sin. B 2022;12(1):406-423. (IF = 11.4

4.Menghang Zu, Dengchao Xie, Brandon S.B. Canup, Nanxi Chen, Yajun Wang, Ruxin Sun, Zhan Zhang, Yuming Fu,* Fangyin Dai,* and Bo Xiao*. ‘Green’ nanotherapeutics from tea leaves for orally targeted prevention and alleviation of colon diseases. Biomaterials 2021; 279: 121178. IF = 12.4

5. Zu M., Ma Y., Cannup B., Xie D., Jung Y., Zhang J., Yang C., Gao F.*, Merlin D.*, and Xiao B.*. Oral delivery of natural active small molecules by polymeric nanoparticles for the treatment of inflammatory bowel diseases. Adv. Drug Deliv. Rev. 2021;176:113887. (IF = 15.4

6. Chen Q., Ma Y., Bai P., Li Q., Canup B., Long D., Ke B., Dai F., Xiao B.,* and Li C.. Tumor Microenvironment-Responsive Nanococktails for Synergistic Enhancement of Cancer Treatment via Cascade Reactions. ACS Appl. Mater. Interfaces 2021;13:4861-4873. IF = 9.3

7. Zhang X., Huang Y., Song H., Canup B.S.B., Gou S., She Z., Dai F.*, Ke B.*, Xiao B.*. Inhibition of growth and lung metastasis of breast cancer by tumor-homing triple-bioresponsive nanotherapeutics. Journal of Controlled Release2020;328:454-469. IF = 9.7

8. Gou S., Yang J., Ma Y., Zhang X., Zu M., Kang T., Liu S., Ke B.*, Xiao B.*. Multi-responsive nanococktails with programmable targeting capacity for imaging-guided mitochondrial phototherapy combined with chemotherapy. Journal of Controlled Release 2020;327: 371-383. IF = 9.7

9. Gou S., Huang Y., Wan Y., Ma Y., Zhou X., Tong X., Huang J.*, Kang Y.*, Pan G., Dai F., Xiao B.*. Multi-bioresponsive silk fibroin-based nanoparticles with on-demand cytoplasmic drug release capacity for CD44-targeted alleviation of ulcerative colitis. Biomaterials 2019;212:39-54.IF = 12.4

10. Xiao B.*, Viennois E., Chen Q., Wang L., Han M., Zhang Y., Zhang Z., Kang Y., Wan Y., Merlin D.. Silencing of Intestinal Glycoprotein CD98 by Orally Targeted Nanoparticles Enhances Chemosensitization of Colon Cancer. ACS nano 2018;12:5253-5265. (IF = 15.8

11. Xiao B*, Chen Q, Zhang Z, Wang L, Denning T, Kang Y, Merlin D. TNFα gene silencing mediated by orally targeted nanoparticles combined with interleukin-22 for synergistic combination therapy of ulcerative colitis. Journal of Controlled Release 2018;287:235-246. IF = 9.7

12. Xiao B.*, Xu Z, Viennois E, Zhang Y, Zhang Z, Zhang M, Han MK, Kang Y, Merlin D. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Molecular Therapy 2017;25(5):1628-1640. IF = 11.4

13. Xiao B.*, Zhang Z, Viennois E, Kang Y, Zhang M, Han MK, Chen J, Merlin D. Combination Therapy for Ulcerative Colitis: Orally Targeted Nanoparticles Prevent Mucosal Damage and Relieve Inflammation. Theranostics 2016;6:2250-66. IF = 11.4

14. Xiao B.*, Zhang M., Viennois E., Zhang Y., Wei N., Baker M.T., Jung Y., Merlin D. Inhibition of MDR1 gene expression and enhancing cellular uptake for effective colon cancer treatment using dual-surface-functionalized nanoparticles. Biomaterials 2015;48:147-160. IF = 12.4

15. Xiao B.*, Laroui H., Viennois E., Ayyadurai S., Charania M.A., Zhang Y., Zhang Z., Baker M.T., Zhang B., Gewirtz A.T., Merlin D.. Nanoparticles with surface antibody against CD98 and carrying CD98 small interfering RNA reduce colitis in mice. Gastroenterology 2014;146(5):1289-1300. IF = 22.6

16.Xiao B.*, Laroui H., Ayyadurai H., Viennois E., Charania M.A., Zhang Y., Merlin D.. Mannosylated bioreducible nanoparticle-mediated macrophage-specic TNF-α RNA interference for IBD therapy. Biomaterials 2013;34(30):7471-82. 直接接收, IF = 12.4

获得的学术奖励

1. 2022年,全球顶尖前10万科学家排名榜单

2. 2021年,国家级高层次青年人才计划

3. 2021年,斯坦福大学发布 2020全球前2%顶尖科学家

4. 2021年,西南大学第二届我心中的好导师

5. 2018年,重庆市特支计划青年拔尖人才

6. 2016年,入选重庆市高等学校青年骨干教师